Diurnal Group PLC Director Dealings (9260J)
16 April 2020 - 11:23PM
UK Regulatory
TIDMDNL
RNS Number : 9260J
Diurnal Group PLC
16 April 2020
16 April 2020
Diurnal Group plc
("Diurnal" or the "Company")
Director Dealings
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical
company targeting patient needs in chronic endocrine (hormonal)
diseases, announces the following Directors' dealings undertaken
for tax planning purposes:
Richard Ross, Chief Scientific Officer sold 125,000 Ordinary
Shares at a price of 30 pence per Ordinary Share; his and his
wife's (Sarah Ross) respective ISAs purchased 125,000 Ordinary
Shares in aggregate at a price of 30.02 pence per Ordinary Share.
Following the transactions, the total beneficial interest of
Richard Ross and his connected parties remains unchanged at
2,182,420 Ordinary Shares, representing 1.8% of the total voting
rights as at 16 April 2020.
Details of the full notifications received by the Company are
set out below:
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Richard Ross
----------------------------- ---------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status Chief Scientific Officer
----------------------------- ---------------------------------------------
b) Initial notification Initial notification
/Amendment
----------------------------- ---------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name Diurnal Group plc
----------------------------- ---------------------------------------------
b) LEI 213800I2HNUNZN1LDH29
----------------------------- ---------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------
a) Description of the Ordinary shares of 5 pence each in
financial instrument, Diurnal Group plc
type of instrument
Identification code GB00BDB6Q760
b) Nature of the transaction Sale and purchase of ordinary shares
----------------------------- ---------------------------------------------
c) Price(s) and volume(s)
--------------------- ----------
Price(s) Volume(s)
--------------------- ----------
Sale 30p 125,000
Purchase 30.02p 62,500
-------------------------------------------------------------- ----------
d) Aggregated information
- Aggregated volume As above
- Price
e) Date of the transaction 16 April 2020
----------------------------- ---------------------------------------------
f) Place of the transaction XLON
----------------------------- ---------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Sarah Ross
--------------------------------- ------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------------
a) Position/status Closely associated person to an Executive
Director
--------------------------------- ------------------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------------- ------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------------
a) Name Diurnal Group plc
--------------------------------- ------------------------------------------------
b) LEI 213800I2HNUNZN1LDH29
--------------------------------- ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------------
a) Description of the Ordinary shares of 5 pence each in
financial instrument, Diurnal Group plc
type of instrument
Identification code GB00BDB6Q760
b) Nature of the transaction Sale and purchase of ordinary shares
--------------------------------- ------------------------------------------------
c) Price(s) and volume(s)
---------------------------- ---------------
Price(s) Volume(s)
---------------------------- ---------------
Purchase 30.02p 62,500
------------------------------------------------------------------- ---------------
d) Aggregated information
- Aggregated volume As above
- Price
e) Date of the transaction 16 April 2020
--------------------------------- ------------------------------------------------
f) Place of the transaction XLON
--------------------------------- ------------------------------------------------
For further information, please visit www.diurnal.co.uk or
contact:
+44 (0)20 3727
Diurnal Group plc 1000
Martin Whitaker, Chief Executive Officer
Richard Bungay, Chief Financial Officer
Panmure Gordon (UK) Limited (Nominated Adviser +44 (0) 20 7886
and Joint Broker) 2500
Corporate Finance: Freddy Crossley, Emma Earl
Corporate Broking: James Stearns
+44 (0)20 7894
Cantor Fitzgerald Europe (Joint Broker) 7000
Corporate Finance: Phil Davies, Will Goode,
Luke Philippou
Healthcare Equity Sales: Andrew Keith
+44 (0)20 3727
FTI Consulting (Media and Investor Relations) 1000
Simon Conway
Victoria Foster Mitchell
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-headquartered, European-based
specialty pharma company developing pharmaceutical products for the
global market for the life-long treatment of chronic endocrine
conditions, including Congenital Adrenal Hyperplasia and Adrenal
Insufficiency. Its expertise and innovative research activities
focus on circadian-based endocrinology to yield novel product
candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit
www.diurnal.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHFLFFVSLIRLII
(END) Dow Jones Newswires
April 16, 2020 09:23 ET (13:23 GMT)
Diurnal (LSE:DNL)
Historical Stock Chart
From Apr 2024 to May 2024
Diurnal (LSE:DNL)
Historical Stock Chart
From May 2023 to May 2024